Clinical Trials Browser

Phase 1 × OTHER × elotuzumab × Clear all

NCT05981209 2026-02-02

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

Phase 1 Recruiting

Multiple Myeloma

NCT02655458 2017-08-18

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

Phase 1 Completed

Multiple Myeloma